CURIA BIO INC

CURIA BIO INC specializes in preclinical biotechnology research and analytical testing services for government-funded life science initiatives. The company delivers end-to-end support for drug development programs, including compliance with current Good Manufacturing Practices (cGMP) for cancer therapeutics and high-complexity sample purification for arboviruses such as dengue and Zika. Their technical expertise spans biopharmaceutical process development, viral vector characterization, and laboratory services requiring stringent quality control, with a demonstrated focus on infectious disease and oncology research. CURIA BIO INC differentiates itself through its ability to bridge early-stage R&D with regulatory-ready analytical workflows, ensuring data integrity and scalability for federal research pipelines. The contractor maintains a strong relationship with the Department of Health and Human Services, providing critical support for public health initiatives centered on infectious disease diagnostics and oncology drug development. Their work for HHS involves translating research outputs into validated, compliant processes suitable for clinical translation, indicating a trusted role in advancing national health priorities through targeted scientific services. CURIA BIO INC operates primarily within NAICS 541714 (biotechnology R&D) and 541380 (testing laboratories), positioning itself at the intersection of discovery science and regulated analytical validation. The company serves the federal biopharma and public health research market by offering specialized laboratory services that support vaccine, antiviral, and oncology pipeline development, with a focus on biosafety level-appropriate handling and analytical rigor. As a small business structured as a 2L entity based in Albany, NY, CURIA BIO INC maintains a focused geographic footprint with no federal certifications on record. Its market positioning reflects a niche capability in high-compliance biotech testing and preclinical development, serving as a specialized contractor for agencies requiring precision, regulatory alignment, and rapid turnaround in complex biological workflows.